At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 176 enrolled
Drug / intervention
EN3835 +1 morebiological
Likely dose
EN3835 8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
In Brief
A Phase 2 clinical trial evaluating EN3835 and Placebo for Plantar Fibromatosis. Completed, enrolled 176 participants across 43 sites.
Detailed Summary
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of up to 2 treatments of EN3835 vs placebo in participants with plantar fibromatosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlantar Fibromatosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartNov 2021
First PostedDec 2021
Primary CompletionJan 2023
TodayJul 2026
First PostedDec 9, 2021
Enrollment StartNov 29, 2021
Primary CompletionJan 10, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.6 years ago
Interventions
EN3835biological
Participant will receive a maximum dose of up to1.8mg of EN3835 injection
Placeboother
Participant will receive a matched Placebo injection